Children’s Hospital Los Angeles Finds Differences in How Doctors, Caregivers and Patients Report Side Effects of Cancer Therapy

Researchers find that doctors underestimate and caregivers overestimate symptoms LOS ANGELES–(BUSINESS WIRE)–A recent study reveals differences in how symptom toxicity is reported for children receiving cancer treatment in clinical trials. Doctors often underestimate or miss a child’s symptoms, while caregivers tend to overestimate symptoms. Children’s Hospital Los Angeles was one of nine hospitals that participated … [Read more…]

Advanced Hepatocellular Carcinoma with CPB Liver Cirrhosis Epidemiology and Market Report 2022 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Advanced Hepatocellular Carcinoma with CPB Liver Cirrhosis – Market Insight, Epidemiology and Market Forecast -2032” report has been added to ResearchAndMarkets.com’s offering. This “Advanced Hepatocellular Carcinoma with CPB Liver Cirrhosis- Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Advanced Hepatocellular Carcinoma with CPB Liver Cirrhosis, historical and forecasted … [Read more…]

Dravet Syndrome Treatment Market Report 2022-2029: Stiripentol and Cannabidiol to Contribute to Significant Growth of 11.7% – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Dravet Syndrome Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 To 2029” report has been added to ResearchAndMarkets.com’s offering. Industry Outlook Dravet syndrome treatment accounted for a market value of US$ 258.1 Mn in 2020 and projected to grow at a CAGR of … [Read more…]

Chronic Kidney Disease Epidemiology and Market Report 2022 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Chronic Kidney Disease – Market Insight, Epidemiology and Market Forecast -2032” report has been added to ResearchAndMarkets.com’s offering. This “Chronic Kidney Disease- Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Chronic Kidney Disease, historical and forecasted epidemiology as well as the Chronic Kidney Disease market trends in the … [Read more…]

Cansativa Group and Akanda Corp. to Bring New Medical Cannabis Flowers to Germany

FRANKFURT AM MAIN & LONDON–(BUSINESS WIRE)–Akanda Corp. (“Akanda”) (NASDAQ: AKAN) and Cansativa GmbH (“Cansativa Group”) today jointly announced a new cooperation that will soon allow German pharmacies to provide patients with two novel cannabis cultivars. This collaboration allows the Cansativa platform to supply the German market with dried flowers from Akanda’s EU-GMP certified indoor grow … [Read more…]

Abionic Receives IVDR Certification for Its Predictive Ultra-Rapid Sepsis Test Allowing the Management of Antibiotic Administration

BSI certification agency has granted Abionic’s abioSCOPE® device and PSP test the IVDR certification for in-vitro diagnostics. This certification complies with Europe’s new In-vitro Diagnostic Regulation (IVDR), and will be required for products sold within the EU from May 2022 onward. A transitional regulation allows established, non-IVDR-certified products to be sold and used if they … [Read more…]

CORRECTING and REPLACING Cybin Announces Up to USD$35 Million At-The-Market Equity Program

TORONTO–(BUSINESS WIRE)–First paragraph, first sentence of release should read: Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, announced today that it has established an at-the-market equity program (the “ATM Program”) that allows Cybin to issue and sell up to USD$35,000,000 of common shares … [Read more…]

Mathai Mammen, M.D., Ph.D., Leaves Position as Executive Vice President, Pharmaceuticals, R&D, Johnson & Johnson

NEW BRUNSWICK, N.J.–(BUSINESS WIRE)–Johnson & Johnson (NYSE: JNJ) (“the Company”) announced today that Mathai Mammen, M.D., Ph.D., has decided to leave his position as Executive Vice President, Pharmaceuticals, R&D, and pursue other opportunities outside of the Company. William Hait, M.D., Ph.D., will serve as interim head of the Pharmaceutical R&D organization until new leadership is … [Read more…]

Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15

Approximately 6,000 participants 5 years of age and older will be enrolled in Lyme disease-endemic regions in Europe and the U.S.  NEW YORK & SAINT-HERBLAIN, France–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced the initiation of a Phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists (VALOR) … [Read more…]